Research map: Advancing antibody drug conjugates in gastrointestinal cancers

Back to the article

Papers in this map

  1. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries · Freddie Bray · 2024 · 26051 citations · Cited by this paper
  2. Circulating tumor-associated autoantibody signatures for diagnosis and prognosis in small-cell lung cancer and lung adenocarcinoma · 2026 · Related
  3. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial · Yelena Yuriy Janjigian · 2021 · 3119 citations · Cited by this paper
  4. High KPNA2 expression predicts poor prognosis in pathological T4 colorectal cancer by importing c-Myc into the nucleus to suppress p53-dependent p21 expression · 2026 · Related
  5. Drug penetration in solid tumours · Andrew Ivor Minchinton · 2006 · 2826 citations · Cited by this paper
  6. Efficacy and safety of infigratinib in patients with refractory advanced gastric or gastroesophageal junction adenocarcinoma harboring FGFR2 gene amplification: a single-arm, multicenter phase 2 trial · 2026 · Related
  7. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab · Hyun‐Soo Cho · 2003 · 1650 citations · Cited by this paper
  8. Reactivation of DRP1 plays a functional role in resistance to MEK inhibition in pancreatic cancer cells · 2026 · Related
  9. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer · Kohei Shitara · 2020 · 1352 citations · Cited by this paper
  10. Interpreting the adverse esophageal and colorectal findings in the Cancer Risk in Vegetarians Consortium · 2026 · Related
  11. DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1 · Yusuke Ogitani · 2016 · 1193 citations · Cited by this paper
  12. AKR1B10 as a serum marker for diagnosis and postoperative monitoring of hepatocellular carcinoma · 2026 · Related
  13. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors · Timothy Richard Wilson · 2012 · 1139 citations · Cited by this paper
  14. Revisiting retinoic acid in AML therapy: mechanisms of action and rational combination strategies · 2026 · Related
  15. HER2-targeted therapies — a role beyond breast cancer · Do‐Youn Oh · 2019 · 1103 citations · Cited by this paper
  16. Targeting Siglec-engaging immunosuppressive sialoglycans to suppress prostate cancer bone metastasis · 2026 · Related
  17. Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial · Funda Meric‐Bernstam · 2023 · 1061 citations · Cited by this paper
  18. Signatures of micropeptides encoded by lncRNAs in cancer progression and metastasis · 2026 · Related
  19. Antibody–drug conjugates come of age in oncology · Charles Dumontet · 2023 · 849 citations · Cited by this paper
  20. Expression of DLL3 and SEZ6 in the Spectrum of Neuroendocrine Neoplasia · 2025 · Related
  21. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial · Kohei Shitara · 2023 · 826 citations · Cited by this paper
  22. Bystander killing effect of DS ‐8201a, a novel anti‐human epidermal growth factor receptor 2 antibody–drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity · Yusuke Ogitani · 2016 · 752 citations · Cited by this paper
  23. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study · Peter C Thuss-Patience · 2017 · 556 citations · Cited by this paper
  24. Claudin-18 Splice Variant 2 Is a Pan-Cancer Target Suitable for Therapeutic Antibody Development · Uğur Şahin · 2008 · 505 citations · Cited by this paper
  25. Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies · Gail D. Lewis Phillips · 1993 · 497 citations · Cited by this paper
  26. Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer · Gerald W. Prager · 2023 · 464 citations · Cited by this paper
  27. Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial · Salvatore Siena · 2021 · 426 citations · Cited by this paper
  28. Antibody–drug conjugates: Recent advances in linker chemistry · Zheng Su · 2021 · 404 citations · Cited by this paper
  29. AMPLIFICATION OF c-erbB-2 ONCOGENE IN HUMAN ADENOCARCINOMAS IN VIVO · Jun Yokota · 1986 · 395 citations · Cited by this paper
  30. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study · Arvind N. Dasari · 2023 · 351 citations · Cited by this paper
  31. Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study · Eric Van Cutsem · 2023 · 263 citations · Cited by this paper
  32. Payload diversification: a key step in the development of antibody–drug conjugates · Louise Conilh · 2023 · 252 citations · Cited by this paper
  33. Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer · James T. T. Coates · 2021 · 243 citations · Cited by this paper
  34. Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trial · Johann Sebastian De Bono · 2019 · 238 citations · Cited by this paper
  35. Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors · Julia Boshuizen · 2018 · 236 citations · Cited by this paper
  36. Efficacy and safety of a novel anti‐HER2 therapeutic antibody RC48 in patients with HER2‐overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single‐arm phase II study · Zhi Peng · 2021 · 212 citations · Cited by this paper
  37. Claudin 18.2 as a novel therapeutic target · Izuma Nakayama · 2024 · 206 citations · Cited by this paper
  38. The therapeutic window of antibody drug conjugates: A dogma in need of revision · Raffaele Colombo · 2022 · 196 citations · Cited by this paper
  39. Cellular adaptation to cancer therapy along a resistance continuum · Gustavo S. França · 2024 · 188 citations · Cited by this paper

Source: OpenAlex (CC0)